These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25300869)

  • 1. Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation.
    Myers KC; Dandoy C; El-Bietar J; Davies SM; Jodele S
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):379-81. PubMed ID: 25300869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients.
    Myers KC; Lawrence J; Marsh RA; Davies SM; Jodele S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):500-3. PubMed ID: 23211838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
    Richardson PG; Murakami C; Jin Z; Warren D; Momtaz P; Hoppensteadt D; Elias AD; Antin JH; Soiffer R; Spitzer T; Avigan D; Bearman SI; Martin PL; Kurtzberg J; Vredenburgh J; Chen AR; Arai S; Vogelsang G; McDonald GB; Guinan EC
    Blood; 2002 Dec; 100(13):4337-43. PubMed ID: 12393437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients.
    Gloude NJ; Jodele S; Teusink-Cross A; Grimley M; Davies SM; Lane A; Myers KC
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):91-95. PubMed ID: 28939456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
    Richardson PG; Soiffer RJ; Antin JH; Uno H; Jin Z; Kurtzberg J; Martin PL; Steinbach G; Murray KF; Vogelsang GB; Chen AR; Krishnan A; Kernan NA; Avigan DE; Spitzer TR; Shulman HM; Di Salvo DN; Revta C; Warren D; Momtaz P; Bradwin G; Wei LJ; Iacobelli M; McDonald GB; Guinan EC
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):1005-17. PubMed ID: 20167278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
    Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
    Richardson PG; Elias AD; Krishnan A; Wheeler C; Nath R; Hoppensteadt D; Kinchla NM; Neuberg D; Waller EK; Antin JH; Soiffer R; Vredenburgh J; Lill M; Woolfrey AE; Bearman SI; Iacobelli M; Fareed J; Guinan EC
    Blood; 1998 Aug; 92(3):737-44. PubMed ID: 9680339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A; Marshall L; Lancaster D
    Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
    Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
    Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
    Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
    Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
    Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of defibrotide in blood and marrow transplantation.
    Richardson PG; Carreras E; Iacobelli M; Nejadnik B
    Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.
    Cappelli B; Chiesa R; Evangelio C; Biffi A; Roccia T; Frugnoli I; Biral E; Noè A; Fossati M; Finizio V; Miniero R; Napolitano S; Ferrua F; Soliman C; Ciceri F; Roncarolo MG; Marktel S
    Br J Haematol; 2009 Nov; 147(4):554-60. PubMed ID: 19747363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Variability in the Reported Management of Hepatic Veno-Occlusive Disease in Children after Hematopoietic Stem Cell Transplantation.
    Skeens MA; McArthur J; Cheifetz IM; Duncan C; Randolph AG; Stanek J; Lehman L; Bajwa R;
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1823-1828. PubMed ID: 27496218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.
    Triplett BM; Kuttab HI; Kang G; Leung W
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2148-2153. PubMed ID: 26278046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
    Corbacioglu S; Richardson PG
    Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.
    Keating GM
    Clin Drug Investig; 2014 Dec; 34(12):895-904. PubMed ID: 25351934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.